Highest-materiality recent filing
United Health Products partners with NAMSA to sponsor clinical study of CelluSTAT for FDA PMA
NAMSA will serve as regulatory sponsor, seeking an IDE to conduct a clinical study of CelluSTAT Hemostatic Gauze.
United Health Products secures $289,821 convertible note from Alumni Capital at 15% and $4M AMPA
Net proceeds of $250,000 from $289,821 senior convertible note; 15% annual interest; maturity Dec 31, 2026.
United Health Products CFO Kristofer Heaton resigns; CEO Brian Thom assumes interim PFO role
Kristofer Heaton resigned as VP of Finance and Principal Financial Officer effective June 12, 2025, citing personal and professional factors.
United Health Products uplisted to OTCQB; FDA declines IDE for CelluSTAT study
Common stock upgraded from OTC Pink to OTCQB effective May 1, 2025; ticker UEEC.
UHP FDA PMA update: supplemental study needed for organ space, 6-7 month delay
FDA requires additional clinical data for CelluSTAT (HemoStyp) use in intestinal/thoracic procedures.
United Health Products amends equity line pricing terms with White Lion Capital
Amendment No. 2 to Common Stock Purchase Agreement (CSPA) dated June 20, 2024.
United Health Products updates FDA PMA progress for HemoStyp Gauze; amends White Lion agreement
FDA update: batch lot from new mfg shown identical to human trial product; additional lots undergoing consistency testing.
Entered common stock purchase agreement with White Lion Capital for up to $10M over 36 months.
UHP meets with FDA on PMA; manufacturing validation needed for review completion
On July 13, 2022, UHP and its consultant met with FDA team to discuss observations from initial PMA review.
United Health Products settles SEC investigation; former CEO to disgorge $1.02M to company
SEC settlement requires permanent injunctions and $450,000 civil penalty payable over 270 days.
United Health Products settles SEC probe; FDA PMA meeting moved to July 13
Accepted SEC settlement terms; complaint filed June 8, 2022; consent judgment to follow; no terms for individuals Beplate, Schiliro.
United Health Products receives proposed SEC settlement terms including $450K penalty
SEC proposed settlement requires $450,000 civil penalty and permanent injunction against company.
Two directors resign amid SEC investigation; COO steps down but remains in non-officer role
Douglas Beplate resigns as director and chairman; Louis Schiliro resigns as director and COO, effective Feb 28, 2022.
CEO Brian Thom sells shares for tax purposes; holdings rise to 1,368,657 shares
CEO Brian Thom completed open-market sales of common stock to satisfy tax obligations and personal expenses.
United Health Products updates on FDA PMA process and Triton Funds investment
FDA requested details on HemoStyp manufacturing process; UHP implemented GMP software tool and will respond later this month.
Kristofer Heaton resigned from the positions of Vice President of Finance and Principal Financial Officer of United Health Products effective on June 12, 2025, citing consideration of personal and professional factors.
In the interim, United Health Products’ Chief Executive Officer, Brian Thom, will act as the Company’s principal financial officer.
Louis Schiliro submitted his resignation as a director and Chief Operating Officer of the Company, each effective on February 28, 2022
On February 18, 2022 Douglas Beplate submitted his resignation as a director of United Health Products, Inc.
Max materiality 0.75 · Median 0.60 · Most common event other_material